An Open-Label, Phase 1, Multi-Center Study to Evaluate the Safety and Preliminary Anti-Tumor Activity of NT-112 in Human Leukocyte Antigen-C*08:02-Positive Adult Subjects with Unresectable, Advanced and/or Metastatic Solid Tumors That Are Positive fo

Protocol No

NEOGENE-NT-112-301

Staff Member

Mandana Kamgar

Phase

I

Summary

This project is being done to determine the safety of NT-112.

Objective

A Phase1 Study of NT-112 in Patients with Advanced Solid Tumors Positive for KRAS G12D Mutation

Study Sites

Froedtert Hospital

Status

OPEN TO ACCRUAL

An Open-Label, Phase 1, Multi-Center Study to Evaluate the Safety and Preliminary Anti-Tumor Activity of NT-112 in Human Leukocyte Antigen-C*08:02-Positive Adult Subjects with Unresectable, Advanced and/or Metastatic Solid Tumors That Are Positive for the KRAS G12D Mutation